Benzinga | Oct 26, 2021 06:55AM EDT

Mizuho Maintains Neutral on Biogen, Lowers Price Target to $270

Mizuho analyst Salim Syed maintains Biogen (NASDAQ:BIIB) with a Neutral and lowers the price target from $300 to $270.